25 Years of Revolutionary Microplate Reader Technology at SLAS 2015
BMG LABTECH will be exhibiting at the SLAS conference 2015 from February 7-11th in Washington, DC. A visit to booth #0929 promises a personal introduction to BMG LABTECH’s high performance microplate readers and latest innovations.
Since its establishment in Offenburg, Germany, BMG LABTECH has become a world leader in microplate reading due to continuous development of innovative and unique technologies. 25 successful years in the industry attest the quality and reliability of BMG LABTECH’s products and services. BMG LABTECH will showcase its latest devices, the CLARIOstar® with new Atmospheric Control Unit (ACU) and PHERAstar FS, at the SLAS 2015 in Washington DC, booth #0929.
The CLARIOstar® multimode microplate reader offers filter-like performance with advanced LVF MonochromatorsTM that provides increased sensitivity over conventional monochromators. The LVF MonochromatorsTM, along with filters and an UV/ Vis spectrometer can be used for a variety of applications in up to eight different detection modes. With its new Atmospheric Control Unit the CLARIOstar® is able to provide the physiological environment for any cell type, enhancing cell-based microplate assays.
The PHERAstar FS is the ultimate multimode microplate reader for High-Throughput Screening, combining the highest sensitivity with the fastest read times. Thanks to the unique optic module system, simultaneous dual emission, UV/Vis spectrometer, and dedicated AlphaScreen® and TRF Lasers the PHERAstar FS will perform any application with ease and speed, even in 3456-well microplates.
Besides exhibiting, BMG LABTECH will participate in four tutorials. The following topics will give an insight into the science behind the technology: “Ultra-Rapid Detection of Cardiac Contraction: Drug Discovery with Personalized 3D Engineered Heart Tissues” in cooperation with Invivo Science, “SPARCL” in cooperation with Lumigen, “HTRF assay in induced pluripotent stem cell derived cell types” in cooperation with Cellular Dynamics International and Cisbio, and “Characterization of Monoclonal Biologics” in cooperation with Cisbio.